

Evidence, Evaluation, and Ethical Obligations: Looking at Evidence Based Medicine

James Giordano, Ph.D., M.Phil.
Joseph A. Procaccino, Jr., J.D., M.F.S
24 June 2021



Presenters



James Giordano, Ph.D., M.Phil.

**Depts. Neurology & Biochemistry
Pellegrino Center for Clinical Bioethics
Georgetown University Medical Center
and
Defense Medical Ethics Center
Washington, DC**

Joseph A. Procaccino, Jr., J.D., M.F.S.

**Legal Advisor, Department of Medical Ethics Center
and
Adjunct Assistant Professor
Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health
Sciences**

James Giordano, Ph.D., M.Phil.



- James Giordano, Ph.D., M.Phil., is a Bioethicist with the Department of Defense (DoD) Medical Ethics Center (DMEC), Chief of the Neuroethics Studies Program, Scholar-in-Residence, leads the Sub-Program in Military Medical Ethics, and Co-director of the O'Neill-Pellegrino Program in Brain Science and Global Health Law and Policy in the Pellegrino Center for Clinical Bioethics.
- Dr. Giordano is also a Professor in the Departments of Neurology and Biochemistry at Georgetown University Medical Center, Washington, DC, USA. He is a Distinguished Visiting Professor of Brain Science, Health Promotions and Ethics at the Coburg University of Applied Sciences, Coburg, Germany, and was formerly the 2011-2012 J.W. Fulbright Foundation Visiting Professor of Neurosciences and Neuroethics at the Ludwig-Maximilians University, Munich, Germany.
- Dr. Giordano currently serves as Chair of the Neuroethics Program of the Institute of Electrical Electronic Engineers (IEEE) Brain Project, and an appointed member of the Neuroethics, Legal and Social Issues (NELSI) Advisory Panel of the Defense Advanced Research Projects' Agency (DARPA). He has previously served as Research Fellow and Task Leader of the EU Human Brain Project Sub-Project on Dual-Use Brain Science; an appointed member of United States Department of Health and Human Services Secretary's Advisory Council on Human Research Protections (SACHRP); and as Senior Science Advisory Fellow of the Strategic Multilayer Assessment Branch of the Joint Staff of the Pentagon.
- The author of over 290 publications in neuroscience and neuroethics, seven books, and 15 government whitepapers on neurotechnology, ethics and biosecurity, he is an Editor-in-Chief of the international journal Philosophy, Ethics and Humanities in Medicine; Associate Editor of the Cambridge Quarterly of Health Care Ethics; and Contributing Editor of Frontiers in Human Neuroscience.
- His ongoing research addresses the neurobiological bases of neuropsychiatric spectrum disorders; and neuroethical issues arising in and from the development, use and misuse of neuroscientific techniques and neurotechnologies in medicine, public life, global health, and military applications.

Joseph A. Procaccino, Jr., J.D., M.F.S.



- Mr. Procaccino is Legal Advisor for DoD DMEC centered at the Uniformed Services University for the Health Sciences (USUHS), and is an Adjunct Assistant Professor of Preventive Medicine and Biostatistics at USUHS where he teaches Medical Jurisprudence and Bioethical issues. He has been on the faculty at USUHS since 1991. He is also on the faculty of the Defense Department's Medxellence Program. He is currently serving in a re-hired annuitant role.
- Mr. Procaccino has served as the Legal Advisor to the Surgeon General, United States Air Force, and Senior Counsel for Health Affairs for the Air Force Judge Advocate General from 1993 until his retirement from Civil Service in that position in 2017. Prior to that, he was the Senior Medical Law Counsel for the Tort Claims and Litigation Branch of the Air Force Legal Operations Agency, beginning his Air Force tenure with that office in 1978. He also served as the legal representative to the Surgeon General's Medical Practice Review Board and Clinical Investigation Review Committee, and participated in the Department of Defense Health Affairs Committee for Risk Management and Quality Assurance.
- In addition to his government service, Mr. Procaccino has been appointed as an Adjunct Associate Professor teaching Health Law at the University of Maryland Graduate School, an Adjunct Assistant Professor at Central Michigan University, and as an Adjunct Instructor at Georgetown University teaching ethics and medical law.
- Mr. Procaccino was commissioned an officer in the U.S. Army Signal Corps in 1973. He subsequently served in the U.S. Army Reserve in both the Signal Corps and Military Intelligence Branch.
- He holds a Bachelor's Degree in both Classical Humanities and Political Science from George Washington University. He received his Juris Doctor degree from American University and a Master's degree in Forensic Medicine (Sciences) from George Washington University.



DISCLOSURES



- Dr. Giordano and Mr. Procaccino have no relevant financial or non-financial relationships to disclose relating to the content of this activity.
- The views expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of the Department of Defense, nor the U.S. Government.
- This continuing education activity is managed and accredited by the Defense Health Agency, J-7, Continuing Education Program Office (DHA, J-7, CEPO). DHA, J-7, CEPO and all accrediting organizations do not support or endorse any product or service mentioned in this activity.
- DHA, J-7, CEPO staff, as well as activity planners and reviewers have no relevant financial or non-financial interest to disclose.
- Commercial support was not received for this activity.

DISCLAIMER

- The materials and information provided during this training are for informational purposes only and not for the purpose of providing legal advice. Nothing in this presentation creates or is intended to create an attorney-client relationship, and is not a substitute for obtaining legal advice.
- Legal determinations are fact specific, but intended to assist with issue spotting. Consult with your agency counsel to obtain advice with respect to any particular issue or problem.
- Different agencies and services may have different regulatory guidance. Consult your agency-specific requirements.
- Licensed Individual Practitioners (LIPs) are subject to state specific guidance as well as guidance put forth by the U.S. Government and DoD.

Learning Objectives



At the end of the presentation, participants will be able to:

- 1. Define evidence-based medicine (EBM).**
- 2. Differentiate EBM and “medicine-based evidence” (MBE).**
- 3. Discuss the core criteria of any/all EBM/MBE.**
- 4. Describe how EBM/MBE ethically enable the clinician.**
- 5. Outline how EBM/MBE ethically empower the patient.**

Does Evidence Support Utility?

- *“Choose your errors carefully, lest you are nigh to repeat them”*
- **Critical evaluation of specific research approaches**
 - Based on levels/ lines of evidence
 - All are not equal or effective

What Paradigms Facilitate Best Evidence-Based Medicine (EBM)?

General Approach

Pragmatic results that can be used to validate outcomes, elucidate mechanisms or both to demonstrate utility of a technique or paradigm as relevant to a specific domain of medicine.

EBM or *Medicine-Based Evidence*?

- **Studies of outcomes**
 - What works, what doesn't?
- **Studies of mechanisms**
 - What are substrates of effect?
- **Studies of proposed utility**
 - How might effective use occur?
 - Parametric effects in numerous domains:
 - Medical
 - Economic
 - Administrative / Legal
 - Social / Philosophical

EBM and MBE Must...

- **Maintain validity**
- **Maintain reliability**
- **Be elucidative**
- **Be applicable**
- ***“How we gain evidence is often more critical than what evidence we gain”***

Assessing the Evidence

- **What level(s) of evidence necessary?**
- **Acknowledge hierarchical evidence:**
 - **Preclinical studies**
 - **n=1 studies**
 - **Case series**
 - **Controlled studies**
 - **Randomized controlled trial (RCT)**


Issues in EBM

- **Current knowledge base suggests need to expand research paradigms**
 - **As appropriate to enhanced knowledge of mechanisms**
 - **To meet changes in interactive “needs” of patient and clinician (as well as other stakeholders)**


Paradigmatic Revision

- **EBM/MBE paradigms may need to:**
 - **Expand the Randomized Controlled Trial (RCT)**
 - Attribute based randomization
 - Attribute-treatment interaction analyses
 - **Utilize mixed (quantitative/qualitative) methodologies**
 - **Go beyond/outside use of RCT where indicated by level of evidence**
 - **Maintain a translational framework**

Paradigmatic Revision



Paradigmatic Revision



Ethical Value of EBM/MBE

Grounded in moral obligation of maximizing good

Upholding fiduciary nature of the clinical encounter:

- **Physician**
 - Allows for effective evaluation of benefit:burden (risk) ratio
 - Enhances knowledge on all levels necessary for adequate prudence in resolving equipoise/decision-making
 - Affords information available to provide patient in respect for patients' autonomy
- **Patient**
 - Allows adequate informational basis to consent to treatment
 - Affords equity in disparity of vulnerability
 - Allows for participation in resolution of equipoise

Ethical Imperative for Translational Research

- **Normative**

- Grounded in moral obligation of **non-harm**

- How?

- “Harm by ***commission***”

- ie.- a Tx is “bad” and is not identified as such

- “Harm by ***omission***”

- ie.- a Tx has potential “good” that is not recognized

- “Harm by ***interference***”

- ie.- a Tx interferes with use of more effective Tx

- Harm through failure to acknowledge the social good of new knowledge to provide epistemic revision thereby enhancing both the therapeutic and moral agency of medicine

Ethical Obligations

- **What works/what doesn't?**
 - **Addressing the non-harm imperative**
- **In whom does it work?**
 - **Addresses the prudential question of what should be done for a particular patient**
- **In what domains?**
 - **Addresses the need for intellectual virtue to apprehend nature of patient effects**
- **Mechanisms of effect**
 - **Addresses types and levels of knowledge applicable to medicine, fortifying both art and skill**
- **Need to study how we study**
 - **Addresses intellectual honesty and epistemic capital**

Ethical Obligations

“Every branch of medicine involves moral considerations, both as regards to the practitioner and the patient...all contain a moral element...which cannot be neglected without injury to the doctor, to the individual and to society.”

Elizabeth Blackwell, 1889

LOOKING AT EVIDENCE BASED MEDICINE: AN “*ADVOCATUS DIABOLI*” VIEW

JOSEPH A. PROCACCINO, JR., J.D., M.F.S.

LEGAL ADVISOR, DEPARTMENT OF DEFENSE MEDICAL ETHICS CENTER

AND

ADJUNCT ASSISTANT PROFESSOR
DEPARTMENT OF PREVENTIVE MEDICINE AND BIOSTATISTICS
UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES



EVIDENCE BASED MEDICINE

THE MELDING OF:

- BEST EVIDENCE
 - CLINICAL EXPERTISE
 - PATIENT VALUES AND PREFERENCES
-
- GOOD IN THEORY, **BUT**: ARE THESE OF EQUAL VALUE AND CONSIDERATION, OR DOES THE WORD “EVIDENCE” ALLOW “BEST EVIDENCE” TO SUPERSEDE THE OTHER FACTORS IN CONSIDERATION?

ISSUES WITH EVIDENCE BASED MEDICINE

- **MEDICINE: IS IT A SCIENCE, AN ART, OR BOTH?**
 - IF BOTH, WHERE DOES THE PROVIDER'S OWN EXPERIENCE, CONTEXT, UNDERSTANDING OF A PATIENT'S UNIQUENESS, FIT IN?
 - RECOGNITION OF PROVIDER DISCRETION
 - FORCING PROVIDERS TO BE "BOXED IN" TO FOLLOWING ONE "PREFERRED" PATH FOR CARE
 - NOT JUST PATIENT PREFERENCES, BUT WHAT ABOUT PATIENT'S CIRCUMSTANCES?
 - AUTONOMY/CONSENT
- **EVIDENCE BASED MEDICINE IS PREMISED ON EVOLVING FINDINGS AND STANDARDS**
 - DOES NOT CREATE A STABLE "TEXTBOOK" STANDARD, BUT IS A RESULT OF CONTINUALLY CHANGING FINDINGS
 - DOES NOT ALLOW FOR VARIANCE OF SPECIALIZATION OR PROFESSIONAL TRAINING DIFFERENCES
 - MAY NOT PROVIDE FOR PRACTICAL DIFFERENCES RECOGNIZED IN CONVENTIONAL "REASONABLE AND PRUDENT PROVIDER IN SAME OR SIMILAR CIRCUMSTANCES"
 - NEED TO SEARCH FOR "GOLD STANDARD"?

SETTING THE “TRADITIONAL STANDARD OF CARE”

- ***THE MEASUREMENT OF DUTY OWED THE PATIENT BY THE PROVIDER OF CARE, THE BREACH OF WHICH WILL RESULT IN LIABILITY FOR ANY INJURIES WHICH MAY BE CAUSED.***

GENERAL RULE

- **THE STANDARD OF CARE IS:**
 - **THAT OF ANOTHER REASONABLE PROVIDER OF THE SAME SPECIALTY IN SAME OR SIMILAR CIRCUMSTANCES**
- **STANDARDS MAY BE AN EVOLUTIONARY PROCESS**

TANGIBLE FACTORS

- **WRITTEN POLICIES AND GUIDANCE**
 - **STATUTES**
 - **REGULATIONS**
 - **CODES OF CONDUCT**
 - **PROFESSIONAL POLICY POSITIONS**
 - **OPERATING INSTRUCTIONS**
 - **CLINICAL PRACTICE “GUIDELINES” ???**

INTANGIBLE FACTORS

- CUSTOMARY AND ACCEPTED PRACTICE
- DEGREE AND LEVEL OF SPECIALTY
- ADVANCES IN PROFESSION
- PROXIMITY OF SPECIALISTS
- AVAILABILITY OF FACILITIES
- GEOGRAPHY
- *UNIQUE MILITARY REQUIREMENTS*
 - ISSUE OF SYSTEMIC NEGLIGENCE
 - DISCRETIONARY FUNCTION AND FEDERAL SUPREMACY
- ALLOWANCE FOR STANDARDS BASED ON TIME OF INCIDENT

HOW DOES AN EVIDENCE BASED STANDARD AFFECT THE PROVIDER AND OBJECTIVE PATIENT CARE?

- **MAY CREATE AN INCREASED BURDEN FOR PROVIDERS IN MALPRACTICE LITIGATION**
 - **GUIDELINES VS. STANDARDS***
 - REVERSING THE BURDEN OF PROOF?
 - THE “DAMNED IF YOU DO, DAMNED IF YOU DON’T” RESULT
 - DILUTES DEFENSE OF “ACCEPTABLE MINORITY STANDARD”
 - PREVENTS INDIVIDUAL DISCRETION BASED ON UNIQUE PATIENT ISSUES
 - OFF-LABEL USE DRUGS
 - HOLISTIC MEDICINE RECOMMENDATION IN COMBINATION WITH “CONVENTIONAL” MEDICINE
 - TAKING ON THE HIGH RISK PATIENT
- **POTENTIAL CONFLICTS**
 - CLINICAL EVIDENCE STANDARDS BASED ON LABORATORY ANALYSES WITH CAPTURED STAFF OF EXPERTS
 - FINANCIAL INCENTIVE FOR SETTING STANDARDS
 - APPROPRIATION BY THE PHARMACEUTICAL INDUSTRY?

FROM OXFORD ONLINE DICTIONARY

- Dictionary

guideline

[ˈɡaɪdˌlaɪn]

NOUN

- a general rule, principle, or piece of advice.
- *synonyms:*
 - [recommendation](#) · [instruction](#) · [direction](#) · [suggestion](#) · [advice](#) · [regulation](#) · [rule](#) · [requirement](#) · [specification](#) · [prescription](#) · [precept](#) · [principle](#) · [guiding principle](#)

[standard](#) · [criterion](#) · [measure](#) · [gauge](#) · [yardstick](#) · [benchmark](#) · [touchstone](#) · [procedure](#) · [parameter](#) · [constraint](#) · [limit](#)

Oxford Online Dictionary

Oxford University Press 2021

HOW DOES AN EVIDENCE BASED STANDARD AFFECT THE PROVIDER AND OBJECTIVE PATIENT CARE?

- **MAY CREATE AN INCREASED BURDEN FOR PROVIDERS IN MALPRACTICE LITIGATION**

- **GUIDELINES VS. STANDARDS***
 - REVERSING THE BURDEN OF PROOF?
 - THE “DAMNED IF YOU DO, DAMNED IF YOU DON’T” RESULT
 - DILUTES DEFENSE OF “ACCEPTABLE MINORITY STANDARD”
 - PREVENTS INDIVIDUAL DISCRETION BASED ON UNIQUE PATIENT ISSUES
 - OFF-LABEL USE DRUGS
 - HOLISTIC MEDICINE RECOMMENDATION IN COMBINATION WITH “CONVENTIONAL” MEDICINE
 - TAKING ON THE HIGH RISK PATIENT

- **POTENTIAL CONFLICTS**

- CLINICAL EVIDENCE STANDARDS BASED ON LABORATORY ANALYSES WITH CAPTURED STAFF OF EXPERTS
- FINANCIAL INCENTIVE FOR SETTING STANDARDS
 - APPROPRIATION BY THE PHARMACEUTICAL INDUSTRY?

Key Takeaways



- **Analyze legal and ethical complexities utilizing evidence based medicine.**
- **Outline standard of care criteria in determining efficacy of practice.**
- **Identify arguable deficiencies using a pure evidence based medicine approach.**
- **Demonstrate how human factors/preferences as well as the uncertainties in the evolution of medicine affect the determination of the propriety of care given.**

References



- Agraharam, R. & Giordano, J. (2019). On the value of p : Toward improving statistical and translational significance – and value – of studies and the applicability of neurotechnology for precision medicine. *Ethics in Biology, Engineering and Medicine*, 9(1), 17-20.
- Giordano J. (2013). Respite finem: Historicity, heuristics and guidance of science and technology on the 21st century world stage. *Synesis: A Journal of Science, Technology, Ethics and Policy* 4: E1-4.
- Giordano, J., Hutchison, P. & Benedikter, R. (2010). Re-grounding medicine amidst a technological imperative and Post-Modern mindset. *International Journal of Politics, Culture, and Society*, 10(10).
- Boswell, M.V. & Giordano, J. (2009). Evidence-based or evidence-biased: On the need to consider stakeholder values in research assessment. *Pain Physician* 12, 9-12.
- Giordano J. (2006). Good as gold? The randomized controlled trial: pragmatic and ethical issues in pain research. *American Journal of Pain Management*, 16, 68-71.
- Giordano J. (2004). Pain research: Can paradigmatic revision bridge the needs of medicine, scientific philosophy and ethics? *Pain Physician*, 7, 459-463.
- Oxford University Press. (2021.) Guideline. In *Oxford Online Dictionary*. <https://www.oxfordlearnersdictionaries.com/us/definition/english/guideline>

How to Obtain CE/CME Credits



To receive CE/CME credit, you must register by 0745 ET on 25 June 2021 to qualify for the receipt of CE/CME credit or certificate of attendance. You must complete the program posttest and evaluation before collecting your certificate. The posttest and evaluation will be available through 8 July 2021 at 2359 ET. Please complete the following steps to obtain CE/CME credit:

1. Go to URL <https://www.dhaj7-cepo.com/content/jun-2021-ccss-exploring-evidence-based-practice-modern-medicine-primary-care>
2. Search for your course using the **Catalog**, **Calendar**, or **Find a course** search tool.
3. Click on the REGISTER/TAKE COURSE tab.
 - a. If you have previously used the CEPO CMS, click login.
 - b. If you have not previously used the CEPO CMS click register to create a new account.
4. Follow the onscreen prompts to complete the post-activity assessments:
 - a. Read the Accreditation Statement
 - b. Complete the Evaluation
 - c. Take the Posttest
5. After completing the posttest at 80% or above, your certificate will be available for print or download.
6. You can return to the site at any time in the future to print your certificate and transcripts at <https://www.dhaj7-cepo.com/>
7. If you require further support, please contact us at dha.ncr.j7.mbx.cepo-cms-support@mail.mil